This could be groundbreaking news for millions suffering with Alzheimer’s disease.
In just days, the US FDA will decide whether to approve Biogen’s Alzheimer’s disease therapy, aducanumab. If approved, the stock could pop about 70%, says Jefferies analyst Michael Yee, as noted by Barron’s, and fall as much as 40% if it’s rejected.
While approval would be great news for the nearly six million Americans dealing with the disease, “An FDA advisory committee said in November that the data Biogen gathered didn’t prove the drug’s efficacy.” With the US FDA often following the advice of the committee, that could be a potential negative. But there’s still some hope.
In addition, according to BioPharmaDive:
“Called aducanumab, Biogen’s medicine is the latest in a long line of would-be treatments that bind to a type of plaque found in the brains of people with Alzheimer’s.”
“In 2015, early study results showed the drug dramatically cleared plaques from the brain and, in a first, suggested treatment slowed patient’s cognitive decline. Biogen and its development partner Eisai proceeded to invest more than $1 billion in testing over the next five years.”
Here’s hoping something great happens for Alzheimer’s patients.
The post All Eyes Will be on this Biotech June 7, 2021 appeared first on Morningology.
